Blockchain Registration Transaction Record

Nutriband's AVERSA Fentanyl Patch Nears FDA Review with 51% Revenue Surge

Nutriband reports 51% revenue growth, advances AVERSA abuse-deterrent fentanyl patch toward FDA approval with $6.9M cash reserves and projected $200M peak sales.

This development matters significantly as it addresses the critical need for abuse-deterrent opioid medications amid the ongoing opioid crisis. If approved, AVERSA Fentanyl would represent the first transdermal patch with built-in abuse prevention technology, potentially reducing diversion and misuse while maintaining therapeutic benefits for legitimate pain patients. The simplified regulatory pathway without Phase 2 or 3 trials could accelerate availability of this important safety technology. For investors, the substantial sales projections ($80-200M for fentanyl, $130M for buprenorphine) indicate major market potential in the multi-billion dollar pain management sector, while for healthcare providers and patients, it offers a safer alternative to current opioid delivery systems.